Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations
- PMID: 6737249
- DOI: 10.1002/jps.2600730530
Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations
Abstract
The bioavailability of isosorbide dinitrate from formulations containing 5, 10, and 20 mg in tablets and 10 mg in solution for oral use and 5 mg in tablets for sublingual use, has been compared. When adjusted for dose, the peak mean plasma drug concentrations after oral administration were similar (e.g., 9.2 ng/mL after a 10-mg tablet) and about one-half that obtained after sublingual administration. Drug concentrations declined monoexponentially with mean half-lives ranging from 25-36 min. The relative bioavailability of isosorbide dinitrate from the oral formulations was not significantly different (p greater than 0.05) over the dose range studied, whereas the relative bioavailability after sublingual administration was about twice as great (p less than 0.01) as that after oral administration. The plasma drug concentration-time profile after administering the 5-mg sublingual tablet was similar to that obtained after administering orally a solution containing 10 mg, indicating that the latter should be as clinically effective as the former.
Similar articles
-
Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations.J Pharm Sci. 1977 Jun;66(6):775-8. doi: 10.1002/jps.2600660607. J Pharm Sci. 1977. PMID: 577507
-
Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects.J Clin Pharmacol. 1978 Nov-Dec;18(11-12):544-8. doi: 10.1002/j.1552-4604.1978.tb01583.x. J Clin Pharmacol. 1978. PMID: 721951
-
Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects.Arzneimittelforschung. 1977;27(1):156-8. Arzneimittelforschung. 1977. PMID: 576817 Clinical Trial.
-
Clinical pharmacokinetics of organic nitrates.Clin Pharmacokinet. 1983 Sep-Oct;8(5):410-21. doi: 10.2165/00003088-198308050-00003. Clin Pharmacokinet. 1983. PMID: 6414751 Review.
-
Pharmacokinetics of organic nitrates in man: an overview.Eur Heart J. 1988 Jan;9 Suppl A:33-7. doi: 10.1093/eurheartj/9.suppl_a.33. Eur Heart J. 1988. PMID: 3137070 Review.
Cited by
-
Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration.Eur J Clin Pharmacol. 1994;46(4):319-24. doi: 10.1007/BF00194399. Eur J Clin Pharmacol. 1994. PMID: 7957516 Clinical Trial.
-
Response to changing plasma concentrations of isosorbide-bound NO2 during acute and sustained treatment with isosorbide dinitrate in patients with coronary artery disease.Clin Cardiol. 2000 Jun;23(6):427-32. doi: 10.1002/clc.4960230610. Clin Cardiol. 2000. PMID: 10875033 Free PMC article.
-
Pharmacokinetics of isosorbide dinitrate, isosorbide-2-nitrate and isosorbide-5-nitrate in renal insufficiency after repeated oral dosage.Klin Wochenschr. 1989 Mar 15;67(6):342-8. doi: 10.1007/BF01741389. Klin Wochenschr. 1989. PMID: 2709744
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources